A recentBrazilian study20, which included51 patients treated with trastuzumab for advanced HER2-positive breast cancer, hasshown that at the third month of treatment, clinical and biochemical data (troponinand NT-proBNP measurements) were not statistically different at the beginning andafter 3 months of treatment with trastuzumab. This evidence concerns the gene ERBB2 and breast cancer.